Posted On: 20 Aug 2025
HaemaLogiX CEO Damian Clarke-Bruce recently presented at the 19th Bioshares Biotech Summit in Hobart, Tasmania, highlighting the company’s pioneering approach to tackling multiple myeloma, the second most common blood cancer.
With two lead therapies in development, including KappaMab, a novel monoclonal antibody, and KMA.CAR-T, a first-in-class cell therapy, HaemaLogiX is advancing treatments designed to target cancerous plasma cells while preserving healthy immune function. Mr Clarke-Bruce outlined the company’s strong clinical results, robust intellectual property, and the potential to transform patient outcomes in the US$23.3 billion global myeloma market.
View the full presentation here.